Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile

NEW YORK, Oct. 6 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile

http://www.reportlinker.com/p0151768/Reportlinker-Adds-Novo-Nordisk-A/S-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Novo Nordisk in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Novo Nordisk’s performance against key rivals in the prescription pharmaceutical sector

*Assess the company’s highly focused strategy, centered on the use of therapeutic proteins and internally sourced R&D

*Analyze how Novo Nordisk’s dominance in the diabetes market will elevate the company to the Big Pharma peer set by 2010

TABLE OF CONTENTS

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Data sourcing 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

Novo Nordisk: PharmaVitae forecasts at a glance 8

Strategic insight 9

SWOT analysis 12

Chapter 3 Quarterly news update 22

Quarterly sales update, Q2 2009 22

Product developments 22

Deals and alliances 23

M&A activity 24

Company announcements 24

Future product milestones 25

Chapter 4 Company introduction 26

Key findings 26

Background 27

Key corporate developments 27

M&A history 28

Current corporate structure 30

Chapter 5 Company sales 32

Key findings 32

Prescription pharmaceutical sales and growth rate analysis, 2002-14 33

Product analysis 35

Therapy area analysis 43

Geographic analysis 46

Launch/core/expiry analysis 49

Molecule type analysis 56

Externalization analysis 59

Chapter 6 Company financials 61

Key findings 61

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 62

Operating costs and profit analysis 63

Chapter 7 Key products and competitors 69

Key findings 69

Overview 70

Diabetes market overview 71

Endocrine, metabolic & genetic disorders 77

Hematology 94

Chapter 8 Appendix 97

R&D pipeline 97

References 98

Abbreviations 98

Exchange rates 100

About Datamonitor 101

Datamonitor consulting 101

Disclaimer 103

TABLE OF TABLES

Table 1: Novo Nordisk – PharmaVitae forecasts at a glance 8

Table 2: Novo Nordisk key product developments, 2009 22

Table 3: Novo Nordisk product deals and alliances, 2009 23

Table 4: Novo Nordisk technology deals and alliances, 2009 23

Table 5: Novo Nordisk M&A activity, 2009 24

Table 6: Novo Nordisk company announcements, 2009 24

Table 7: Novo Nordisk future product milestones, 2009-11 25

Table 8: Novo Nordisk product portfolio overview ($m), 2002-08 36

Table 9: Novo Nordisk product portfolio overview ($m), 2008-14 39

Table 10: Novo Nordisk prescription pharmaceutical sales by therapy area ($m), 2008-14 44

Table 11: Novo Nordisk prescription pharmaceutical sales by geographic region ($m), 2008-14 47

Table 12: Novo Nordisk launch portfolio overview ($m), 2008-14 50

Table 13: Novo Nordisk core portfolio overview ($m), 2008-14 52

Table 14: Novo Nordisk expiry portfolio overview ($m), 2008-14 53

Table 15: Novo Nordisk prescription pharmaceutical sales by molecule type ($m), 2008-14 57

Table 16: Novo Nordisk prescription pharmaceutical sales by source ($m), 2008-14 60

Table 17: Total Novo Nordisk sales by business unit ($m), 2002-08 62

Table 18: Novo Nordisk operating revenue/cost analysis ($m), 2002-08 64

Table 19: Novo Nordisk operating cost ratio analysis (% of total revenues), 2002-08 66

Table 20: Novo Nordisk operating cost ratio analysis (% of total revenues), 2008-14 67

Table 21: Novo Nordisk operating revenue/cost analysis ($m), 2008-14 68

Table 22: Key products overview 70

Table 23: Key insulin antidiabetics in 2008 74

Table 24: Key non-insulin antidiabetics in 2008 75

Table 25: NovoRapid: overview 77

Table 26: NovoRapid: sales forecast ($m), 2008-14 78

Table 27: NovoMix: overview 80

Table 28: NovoMix: sales forecast ($m), 2008-14 81

Table 29: Levemir: overview 83

Table 30: Levemir: sales forecast ($m), 2008-14 84

Table 31: Actraphane: overview 86

Table 32: Actraphane: sales forecast ($m), 2008-14 87

Table 33: Victoza: overview 88

Table 34: Victoza: sales forecast ($m), 2008-14 89

Table 35: Norditropin: overview 92

Table 36: Norditropin: sales forecast ($m), 2008-14 93

Table 37: NovoSeven: overview 94

Table 38: NovoSeven: sales forecast ($m), 2008-14 95

Table 39: Key hemophilia products in 2008 95

Table 40: Novo Nordisk’s R&D pipeline (Phase I-registration) 97

Table 41: Exchange rates, 2009 100

TABLE OF FIGURES

Figure 1: The PharmaVitae Explorer 3

Figure 2: Novo Nordisk prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Novo Nordisk’s financial performance ($m), 2002-14 7

Figure 4: Novo Nordisk presence in its key target markets (% of total market revenue), 2002-14 9

Figure 5: Novo Nordisk SWOT analysis 12

Figure 6: Novo Nordisk corporate history 27

Figure 7: Novo Nordisk corporate structure 30

Figure 8: Pharmaceuticals business unit structure, % of total annual revenue 31

Figure 9: Novo Nordisk prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 33

Figure 10: Key product sales ($m), 2002-14 35

Figure 11: Novo Nordisk key sales growth drivers and resistors ($m), 2002-08 37

Figure 12: Novo Nordisk key sales growth drivers and resistors ($m), 2008-14 40

Figure 13: Novo Nordisk prescription pharmaceutical sales by therapy area ($m), 2002-14 43

Figure 14: Novo Nordisk prescription pharmaceutical sales by geographic region ($m), 2002-14 46

Figure 15: Novo Nordisk launch/core/expiry configuration ($m), 2008-14 55

Figure 16: Novo Nordisk prescription pharmaceutical sales by molecule type ($m), 2002-14 56

Figure 17: Novo Nordisk prescription pharmaceutical sales by source ($m), 2002-14 59

Figure 18: Novo Nordisk operating revenue/cost analysis ($m), 2002-14 63

Figure 19: Key competitors to Novo Nordisk in the antidiabetics market 73

To order this report:

Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile

http://www.reportlinker.com/p0151768/Reportlinker-Adds-Novo-Nordisk-A/S-PharmaVitae-Profile.html

More market research reports here!

    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)-652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker